Table 5.
Effect of Gaboxadol on PSG Sleep Architecture in Adult Primary Insomnia Patients: Mean (SD) Min Spent in Each Sleep Stage
| Time | N | Stage 1 | Stage 2 | Stage 3 | Stage 4 | REM |
|---|---|---|---|---|---|---|
| Nights 1/2 | ||||||
| Placebo | 156 | 38.0 (18.1) | 202.5 (39.1) | 28.6 (16.1) | 20.1 (22.9) | 74.9 (24.2) |
| Gaboxadol 10 mg | 153 | 35.9 (19.1) | 207.6 (37.7) | 31.2 (18.1) | 25.4 (28.2)** | 75.0 (22.3) |
| Gaboxadol 15 mg | 148 | 33.4 (15.4) ** | 207.6 (43.0) | 35.7 (21.0)*** | 30.7 (29.3)*** | 79.4 (23.8) |
| Nights 29/30 | ||||||
| Placebo | 144 | 37.1 (17.9) | 212.8 (41.8) | 29.6 (17.3) | 21.3 (23.8) | 78.7 (25.0) |
| Gaboxadol 10 mg | 145 | 34.5 (18.0)* | 211.9 (38.5) | 32.8 (18.2) | 25.6 (27.1)* | 77.1 (21.5) |
| Gaboxadol 15 mg | 131 | 33.1 (15.4)*** | 214.2 (41.6) | 34.5 (18.3)** | 29.9 (29.5)*** | 82.4 (22.3) |
*
P ≤ 0.05,
**
P < 0.01,
***
P < 0.001 versus placebo (nominal P values); analysis based on differences between treatments in change from baseline duration in min.